December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

41.49 +1.79 (+4.51%)
Streaming Delayed Price Updated: 12:11 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Harrow Inc (NASDAQ:HROW) Presents a Compelling Case for Affordable Growth ↗
Via Chartmill
News headline image
Harrow Inc (NASDAQ:HROW) Presents a Growth and Breakout Opportunity ↗
Harrow Inc. (HROW) combines explosive projected earnings growth with a technical chart setup suggesting a potential breakout, aligning fundamentals with price action. 
Via Chartmill
HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price ↗
Via Chartmill
News headline image
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal? ↗
This ophthalmic pharma specialist -- known for its compounded medications and royalty streams -- just reported a big insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
Harrow Inc (NASDAQ:HROW) Stock Plummets 13% After Q4 Earnings Miss ↗
Via Chartmill
HARROW INC (NASDAQ:HROW) Emerges as a High-Growth Momentum Stock with Strong Technical Setup ↗
Via Chartmill
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
What's going on in today's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Harrow (HROW) Q4 2025 Earnings Call Transcript ↗
Harrow (HROW) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside ↗
Via Stocktwits
Which stocks are gapping on Tuesday? ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗
Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Outset Medical, Gemini Space Station, CoreWeave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Demystifying Harrow: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
A Preview Of Harrow's Earnings ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? ↗
Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it has agreed to acquire Melt 
Via Benzinga
News headline image
Tesla To Rally Around 4%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
HARROW INC (NASDAQ:HROW) Presents High Growth Momentum and Technical Breakout Opportunity ↗
Harrow Inc (HROW) is a high-growth ophthalmic pharma stock with strong revenue expansion and a bullish technical breakout setup, signaling potential upward momentum. 
Via Chartmill
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy ↗
Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy. 
Via Benzinga
News headline image
Assessing Harrow: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock ↗
Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money." 
Via Benzinga
News headline image
Where Harrow Stands With Analysts ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.